Rifampin Capsules USP — Class II drug recall D-0437-2024
Terminated recall by Lupin Pharmaceuticals Inc., reported 2024-04-17, distributed nationwide. Subpotent Drug
| Recall number | D-0437-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2024-03-21 |
| Classified | 2024-04-05 |
| Reported by FDA | 2024-04-17 |
| Terminated | 2025-04-04 |
| Distributed | Nationwide (US) |
| Quantity | 26,352 bottles |
| Reason classes | potency |
| NDC | 06818-0659-06 |
| Lot numbers | A201064 |
| Expiration dates | 2024-03-20 |
Product
Rifampin Capsules USP, 300mg, 30-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India, NDC 6818-0659-06
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0437-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.